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Recent research on the standard of care and related quality of life 
of the spinal cord-afflicted community in South Africa (SA) has 
revealed significant gaps in practice, and challenges regarding levels 
of care and access to services and supplies specifically related to the 
neurogenic bladder.[1]
There is evidence that people with disabilities experience 
poorer health outcomes than the general population. People with 
spinal cord afflictions (SCAs) are at higher risk of secondary 
conditions such as pneumonia, pressure ulcers and urinary 
tract infections (UTIs). These conditions frequently lead to 
hospitalisation, and can also result in increased costs for care, 
reduced employability, decreased quality of life and lowered life 
expectancy.[2]
In response to this, the Continence Advisory Panel (CAP), under 
the auspices of the Southern African Spinal Cord Association 
(SASCA), has produced these best practice recommendations to 
further evidence-based bladder management (mainly in the spinal 
cord-afflicted) that ensures social continence and appropriate and 
safe drainage of the neurogenic bladder. The recommendations aim 
to prevent unwanted and costly bladder complications (i.e. infections, 
stones, renal reflux and scarring). 
These recommendations have been drawn up in SA by clinicians 
working specifically in the field of rehabilitation medicine and SCA, 
with inputs from urology specialists, and reference to international 
guidelines. They have been adapted to the SA context, drawing from 
the best available international research and clinical expertise when 
making treatment decisions for individual SA patients. 
These recommendations mainly follow those of the European 
Association of Urology (EAU) neuro-urology guidelines (www.
uroweb.org/guidelines/neuro-urology/), which are endorsed by the 
SA Urological Association (SAUA). The 2018 edition of the EAU 
guidelines uses the Grading of Recommendations Assessment, 
Development, and Evaluation (GRADE) group methodology 
across all guidelines, where for each recommendation there is an 
accompanying strength rating based on the overall quality of the 
evidence that exists for the recommendation, as per the Oxford 
Centre for Evidence-Based Medicine Levels of Evidence. Readers are 
advised to consult these and other EAU guidelines that may address 
different aspects of the topics discussed.[3]
These recommendations are in line with the CAP vision[1] to: 
• establish the standard of care for people living with SCAs (speci-
fically relating to continence) who want to lead active and fulfilling 
lives
• improve access to continence care for South Africans through 
education, advocacy and service, thereby improving the standard 
of care, upholding their dignity and enhancing their quality of life.
These SA recommendations are intended to be used by consumers 
(SCA patients), clinicians, policy makers and funders, and should 
be read in conjunction with current international guidelines and 
evidence of clinical best practice and experience, many of which are 
referenced in this paper, in the interests of improving patient-centred 
decision-making and outcomes for all parties involved.
These recommendations should not be viewed as a rewriting of 
any accepted guidelines, but rather as an attempt to draw attention 
to current best practice principles as practised in SA. CAP does not 
intend to promote or impose any particular method or product on 
any individual patient, but we do view it as our responsibility to 
inform them of available alternatives, and the rationale for these 
recommendations.
Bladder management strategies
Bladder management strategies are long-term treatment plans with 
implications for maintaining health and quality of life. To make 
informed choices about the most appropriate method of bladder 
management, consumers, family members and/or carers require 
information about the risks and benefits of the available options.[4] 
These recommendations are consistent with well-entrenched 
principles reflected in international guidelines (mainly the EAU 
guidelines) and prescribed by the International Spinal Cord Society.[5] 
Reference is also made to other publications, mainly from English-
speaking countries, and published since the EAU guidelines.
Consumers with neurogenic urinary tract dysfunction, their family 
members and/or carers need specific information and training. 
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Consumers starting to use, or who are using, individually decided-
upon bladder management strategies require: 
• training, support and review from healthcare professionals, who 
are trained to provide support in the relevant bladder management 
systems and are knowledgeable about the range of products 
available
• access to a range of products and services that meet their needs.[6]
Clean intermittent catheterisation (CIC) is accepted as the gold 
standard for the management of the neurogenic bladder worldwide. 
International literature also refers to clean intermittent self-
catheterisation or intermittent self-catheterisation, or other similar 
terms. Appropriate techniques and selection of catheters are subject 
to specific patient care environments (i.e. sterile, aseptic, no-touch 
and clean techniques).[7] The identification of a carer is an important 
consideration in cases where the consumer is unable to self-catheterise.
The prevalence of complications can be decreased by adequate 
patient education, use of non-traumatising techniques and adequate 
precautions to prevent infections.[8]
Recommendations (phased approach)
Spinal cord services for SCA in SA vary in terms of logistics and 
intensity. Levels of care are delivered at different institutions and 
according to different educational standards.[9]
Care pathways are therefore (for practical purposes) divided into 
three phases in the management of the neurogenic bladder in the 
SA context. This approach is based on the consensus opinion of 
clinicians working with SCA patients, in consultation with peers, 
and best evidence-based practice, defined by Sackett et al.[10] as ‘the 
conscientious, explicit and judicious use of current best evidence in 
making decisions about the care of individual patients’.
Of utmost importance in all three phases is the prevention 
of catheter-associated UTIs, through correct staff and patient 
supervision/training and monitoring, education in hand hygiene 
and the maintenance of the clean closed-loop/circuit principle with 
indwelling catheters (IDCs). 
CIC is the gold standard for all three phases. The average frequency 
of catheterisation is 4 - 8 times per day. It has also been proven to be 
the preferred method of catheterisation in patients with neurogenic 
bladder dysfunction.[8] 
The primary aims (and their order of prioritisation) when treating 
neuro-urological disorders are: 
•	 protection of the upper urinary tract
•	 improvement of urinary continence
•	 restoration of (parts of) the lower urinary tract function
• improvement of the patient’s quality of life.
Phase 1: Early/acute management
After injury, the initial monitoring of physiological stability, including 
urine output, and timely catheterisation, are of utmost importance.
Awareness of urinary retention immediately post-injury 
(catheterisation), preservation of the urethra (limiting prolonged 
transurethral catheterisation) and continence (to prevent pressure 
sores) are the focus in this phase. 
Prolonged indwelling urethral catheterisation is a major cause of 
iatrogenic urethral strictures in SCA males. Urethral strictures can 
cause serious problems for SCA patients wanting to be managed 
with CIC or condom and urinary bag drainage, and should therefore 
be prevented at all costs. Attempts at reconstructive surgical repair 
are far less successful than in the neurologically intact population. 
A urethral stricture can affect the SCA patient’s management for the 
rest of his life.
The option of a suprapubic catheter also needs to be considered. 
Alternatively, aseptic CIC (even in intensive care settings) is a 
worthwhile option, if staff allocation and expertise allow for this. In 
the aseptic technique, the catheter remains sterile, the genitals are 
disinfected and sterile lubricant is used.[8]
If the staff/healthcare professional(s) have little or no experience 
in SCA management, the help of a urologist (with an interest in SCA 
urology) should be sought to assist in its correct management. The 
same principle applies to any complications related to neurogenic 
bladder management (e.g. traumatic catheterisations or possible 
renal/bladder injuries).
The early detection and treatment of UTIs is vital in this phase, as 
this can prevent long-term damage.
Further important considerations during this phase are the extent 
of the patient’s disability, cost-effectiveness, technical complexity and 
possible comorbid complications.
Phase 2: Rehabilitation (preferably in a specialised 
centre)
Establishing the suitability of the patient with SCA for CIC needs to be 
the top priority in this phase, if it has not already been implemented. 
Care needs to be taken in patient selection, as patient insight and 
compliance are vital for success in intermittent catheterisation (Table 1).
The dexterity and mental capacity of the SCA patient, and/or 
the availability of a willing caregiver to perform the catheterisation, 
must be paramount factors in the decision-making process. Avoid 
intermittent catheterisation in individuals with SCA with one or 
more of the following:[11] 
• inability to catheterise themselves
• a carer who is unwilling to perform catheterisation
• abnormal urethral anatomy, such as stricture, false passages or 
bladder neck obstruction
• bladder capacity <200 mL
• poor cognition, little motivation, inability or unwillingness to 
adhere to the catheterisation time schedule
• high fluid intake regimen
• adverse reaction to passing a catheter into the genital area multiple 
times a day
Table 1. Evidence and recommendations for catheterisation in patients with SCAs[3]
Summary of evidence LE
Intermittent catheterisation is the standard treatment for patients who are unable to empty their bladder. 3
Recommendation Strength rating
 Use intermittent catheterisation, whenever possible aseptic technique, as a standard treatment for patients unable to empty 
their bladder.
Strong
Thoroughly instruct patients in the technique and risks of intermittent catheterisation. Strong
Avoid indwelling transurethral and suprapubic catheterisation whenever possible. Strong
SCA = spinal cord affliction; LE = level of evidence.
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• tendency to develop autonomic dysreflexia with bladder filling/
urethral instrumentation, despite treatment. 
It is recommended that a choice of either single-use hydrophilic or 
gel reservoir catheters for intermittent self-catheterisation should be 
offered.[12] The gold standard in CIC remains a new sterile catheter, 
because of the decreased risk of infection.[13]
Numerous general medical and social factors also need to be 
considered when dealing with urinary incontinence (a checklist 
might be of benefit in this).[14} A dedicated multidisciplinary approach 
with all SCA patients is vital to attaining a good outcome and long-
term success.
If IDC is decided upon, a silastic catheter must be used, and 
changed every 4 - 6 weeks. Latex catheters should not be used for 
long-term catheterisation.
If condom and bag drainage is the choice determined on, the 
general changing interval is 1 - 3 days.
Important factors during rehabilitation phase
Minimum investigations to appropriately assess the neurogenic bladder:
• A urodynamic study (UDS) needs to be performed approximately 
3 months post injury, or at the discretion of the treating SCA 
physician/urologist. The UDS is an essential tool in neurogenic 
bladder assessment, and is crucial in deciding what choice of 
bladder management is selected. It is internationally accepted that 
reflex neurogenic activity of the SCA bladder has usually returned 
3 months post injury. A patient in whom normal sensory voiding 
(with acceptable residual urine) returns within a few weeks of the 
injury does not need a UDS (Table 2).
• Uroflowmetry or genitourinary ultrasound assessment of post-
void residual urine should be repeated at least two or three times 
in patients who are able to void. 
• Abdominal X-ray (AXR), including the pelvis, and ultrasound 
of kidneys and bladder should be performed. An intravenous 
pyelogram is an optional investigation. The initial ultrasound and 
AXR can be done as an inpatient.
• A CT scan, with or without contrast, is an important investigation 
in suspected upper tract pathology.
Assisted bladder emptying (caution)
Triggered reflex voiding is not recommended, as there is a risk of 
pathologically elevated bladder pressures. Only in the case of absence 
of, or surgically reduced, outlet obstruction may it be an option.
Caution: bladder compression techniques to expel urine (Credé) 
and voiding by abdominal straining (Valsalva manoeuvre) create 
high pressures and are potentially hazardous, and their use should 
be discouraged.
Pharmacological considerations
Urological drugs initiated during this phase are to be prescribed by 
an experienced SCA clinician, or in consultation with a urologist 
(Table 3).
Bowel management
A consistent and effective bowel management programme is 
essential to the urological health of SCA patients, as constipation/
faecal impaction will negatively affect their general wellbeing, and 
specifically urological outcomes.
Table 2. Evidence and recommendations for urodynamics and uro-neurophysiology[3]
Summary of evidence LE
Urodynamic investigation is the only method that can objectively assess the (dys)function of the LUT. 2a
Video-urodynamics* is the optimum procedure for urodynamic investigation in neuro-urological disorders. 4
Specific uro-neurophysiological tests are elective procedures and should only be carried out in specialised settings. 4
Recommendation Strength rating
Non-invasive testing is mandatory before invasive urodynamics is planned. Strong
Perform a urodynamic investigation to detect and specify lower urinary tract (dys)function, use same-session repeat 
measurement, as it is crucial in clinical decision-making.
Strong
Use video-urodynamics for invasive urodynamics in neuro-urological patients. If this is not available, then perform 
a filling cystometry continuing into a pressure flow study.
Strong
Use a physiological filling rate and body-warm saline. Strong
LE = level of evidence; LUT = lower urinary tract.
*Video urodynamics combines filling cystometry and pressure flow studies with radiological imaging. Currently, video urodynamics is considered to provide the most comprehensive information 
for evaluating neuro-urological disorders.
Table 3. Summary of evidence and recommendations on drug treatment[3]
Summary of evidence LE
Long-term efficacy and safety of antimuscarinic therapy for neurogenic detrusor overactivity is well documented. 1a
A significant reduction in adverse events was observed for intravesical administration of oxybutynine compared with
oral administration.
1a
Maximise outcomes for neurogenic detrusor overactivity by considering a combination of antimuscarinic agents. 3
Recommendations Strength rating
Use antimuscarinic therapy as the first-line medical treatment for neurogenic detrusor overactivity. Strong
Offer intravesical oxybutynin to patients with neurogenic detrusor overactivity with poor tolerance to the oral route. Strong
Prescribe α-blockers to decrease bladder outlet resistance. Strong
Do not prescribe parasympathomimetics for underactive detrusor. Strong
LE = level of evidence.
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Autonomic dysreflexia
The early detection and management of autonomic dysreflexia 
is imperative in the SCA population, as this condition can be 
potentially life-threatening. This usually occurs only in lesions above 
T7 (potentially ‘unsafe’ bladder).
Phase 3: Post discharge/rehabilitation 
It is widely accepted that urinary tract morbidity ranks as a major 
cause of hospital readmission in individuals with SCA, and is still a 
leading factor in mortality in this population. Adequate phase 1 and 
2 management will improve the prognosis.
Discharge planning is an important part of the rehabilitation 
phase, and must include regular follow-up at a specialised unit or 
by a urologist. Earlier follow-up for high-risk patients (especially on 
CIC) is strongly advised if any doubt exists regarding compliance or 
high-risk behaviour (Table 4).
The importance of early identification of potential SCA 
complications (of which incontinence is a high-risk indicator) 
cannot be underestimated. The correct management of these 
is an important step in the cost-effective and morbidity-saving 
chain of events. For instance, the prevention of one pressure sore 
(which often follows incontinence) can relate to a cost saving of 
approximately ZAR500 000.
Many surgical interventions exist that can improve/restore 
continence in SCA patients (e.g. onabotulinum toxin A, sacral 
anterior root stimulators, urinary diversions, artificial sphincters, 
bladder neck procedures, etc.). These fall outside the framework 
of these recommendations, and need specialist and individualised 
decision-making and management plans (Tables 5 and 6).
The biggest challenge in phase 3 is the absence of readily 
available resources. The Patient Rights Charter of SA stipulates 
the right to basic medical care. In the SCA field, this means the 
right to the provision of adequate basic medical care that includes 
the supply of sundries (for human dignity and health). This 
therefore relates to both the provision of expertise (especially in 
rural areas) and that of basic urological equipment, sundries and 
medication. The changing of urological (and bowel) management 
by inexperienced, well-meaning staff poses a grave danger to the 
health of SCA patients.
Overriding principles for decision-
making
Treatment options
A practical and systematic approach needs to be taken by SA 
clinicians working in the field of SCA. Decision-making on the 
correct management/treatment options needs a dedicated team of 
SCA clinicians in all three phases set out above, and treatment needs 
to be individualised. Input from a urologist with interest in SCA is 
imperative, to widen the range of options open to patients.[15] 
Treatment options currently available/used in the SA context 
include the following: 
• spontaneous voiding
• timed voiding (with/without condom and bag)
• intermittent catheterisation 
• condom and bag (without sensation)
• chronic indwelling catheter
• suprapubic catheter
• intravesical onabotulinum toxin A
• transurethral sphincterotomy
• sacral nerve stimulation (InterStim)
• bladder augmentation
• urinary diversion.
The safety (risk v. benefit) of any of these options needs to be 
evaluated/weighed up for each individual patient. The objective is 
to achieve the least invasive and most effective/safest option. The 
use of medication in any of the above options must be carefully 
considered. Discussion of possible options with the spinal cord-
afflicted individual is mandatory. Individual health status, patient 
insight/compliance, social environment and circumstances need 
to be taken into consideration in this decision. It is not within the 
scope of these recommendations to go into the detail of every step of 
Table 4. Summary of evidence and recommendations for follow-up[3]
Summary of evidence LE
Neuro-urological disorders are often unstable and the symptoms may vary considerably; therefore, regular 
follow-up is necessary.
4
Recommendations Strength rating
Assess the upper urinary tract at regular intervals in high-risk patients. Strong
Perform a physical examination and urine laboratory test every year in high-risk patients. Strong
Any significant clinical changes should instigate further, specialised, investigation. Strong
Perform urodynamic investigation as a mandatory baseline diagnostic intervention in high-risk patients at regular 
intervals.
Strong
LE = level of evidence.
Table 5. Summary of evidence and recommendations for minimal invasive treatment[3]
Summary of evidence LE
Botulinum toxin A has been proven effective in patients with neuro-urological disorders due to MS or SCA in multiple 
RCTs and meta-analyses.
1a
Bladder neck incision is indicated only for secondary changes (fibrosis) at the bladder neck. 4
Recommendations Strength rating
Use botulinum toxin injection in the detrusor to reduce neurogenic detrusor overactivity in multiple sclerosis or spinal 
cord injury patients if antimuscarinic therapy is ineffective.
Strong
Bladder neck incision is effective in a fibrotic bladder neck. Strong
LE = level of evidence; MS = multiple sclerosis; SCA = spinal cord affliction; RCT = randomised controlled trial.
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the possible options. The approach is in line with the international, 
commonly used clinical guidelines.[11,16]
Urinary tract infection prevention
UTIs present in challenging or insidious ways in the spinal cord 
afflicted population. Clinical experience in recognising a symptom 
complex in these patients is helpful, and will reduce the inappropriate 
use of antibiotics. 
The routine use of urinary dipsticks for screening for UTIs is not 
advised. Routine use of antibiotic prophylaxis is discouraged and 
reserved for exceptional cases when all other avenues have been 
explored. Investigation of underlying contributing factors (bowel, 
bladder emptying and structural abnormalities) is mandatory.
General rules applicable to the use of antibiotics in the 
neurogenic bladder
• Treat bacteriuria only if symptomatic (bacterial colonisation does 
not require treatment).
• Urine microscopy, culture and sensitivity (MCS) is mandatory 
prior to initiating antibiotics in symptomatic patients, but it should 
not delay prompt treatment.
• Choose antimicrobials with as little impact on bowel flora as 
possible.
• Adjust antibiotics according to sensitivity of organism.
• Treat proven infections for at least 5 days. Re-infections are treated 
for 7 - 14 days.
• Repair structural and functional risk factors.
• Prophylaxis only to be used in recurrent infections and in 
consultation with experienced clinicians/urologist.
• Patients with indwelling catheters should not be given routine 
antibiotic prophylaxis.
Clean intermittent catheterisation 
practices
Current view 
Intermittent catheterisation was introduced in the 1970s and is now 
considered the gold standard for the management of neurogenic 
bladder dysfunction.
International guidelines (e.g. by the EAU and the National Institute 
for Health and Care Excellence) do not explicitly recommend single-
use over multiple-use catheters, but propose a patient-oriented choice, 
with specific reference to patient-specific requirements. We subscribe 
to this recommendation, as it aligns with our obligations as medical 
practitioners, and to the relevant health legislation. We believe that 
patients with SCA need to be empowered to live as independently as 
possible, with the provision of adequate and appropriate continence 
care products to ensure quality of life, medical stability and safety.
The EAU recommends that intermittent catheterisation, whenever 
possible with an aseptic technique, should be standard treatment 
for patients who are unable to empty their bladder. Indwelling 
transurethral and suprapubic catheterisation should be avoided 
wherever possible.[3] 
Aseptic CIC is defined by the EAU as comprising genital 
disinfection and the use of sterile catheters and instruments/
gloves.[3] 
CIC should be implemented in spinal cord-afflicted patients as 
soon as possible after the SCA occurs.
CIC is dependent upon: 
• adequate hand function/dexterity
• absence of cognitive impairment
• full co-operation of the patient.
Spinal cord-afflicted patients require education and training in the 
technique and risks of CIC. This training should include: 
• hand hygiene
• technique of self-catheterisation
• cleaning and storage of catheter (if re-used)
• recognition and awareness of signs and symptoms of UTI, and how 
to access medical advice and treatment
• understanding of adequate fluid intake per 24 hours
• correct size of a catheter, in adults, between 12 and 16 Fr.
Optimal bladder drainage at regular intervals, to prevent bladder 
over-distension, is crucial for the mental health and quality of life of 
people with SCA.[17,18]
There is a lack of uniformity and standardisation in nursing 
practice in terms of performing CIC.[13]
Rationale for single-use hydrophilic intermittent 
catheters
Cardenas et al. [19] report that the use of a hydrophilic-coated catheter 
for CIC is associated with a delay in the onset of the first antibiotic-
treated symptomatic UTI, and a 21% reduction in the incidence of 
symptomatic UTI in patients with acute spinal cord injury (SCI) 
during acute inpatient rehabilitation. Using a hydrophilic-coated 
catheter minimises UTI-related complications, treatment costs and 
Table 6. Summary of evidence and recommendations for surgical treatment[3]
Summary of evidence LE
Bladder augmentation is an effective option to decrease detrusor pressure and increase bladder capacity, when all less-
invasive treatment methods have failed.
3
Urethral sling placement is an established procedure, with acceptable medium- to long-term results, in women with the 
ability to self-catheterise.
3
Artificial urinary sphincter insertion is a viable option, with acceptable long-term outcomes, in males. The complication 
and re-operation rates are higher in neuro-urological patients; therefore, patients must be adequately informed regarding 
the success rates as well as the complications that may occur following the procedure.
3
Recommendations Strength rating
Perform bladder augmentation in order to treat refractory neurogenic detrusor overactivity. Strong
Place an autologous urethral sling in female patients with neurogenic stress urinary incontinence who are able to self-
catheterise.
Strong
Insert an artificial urinary sphincter in male patients with neurogenic stress urinary incontinence. Strong
LE = level of evidence.
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rehabilitation delays, and reduces the emergence of antibiotic-
resistant organisms.
In a recently published meta-analysis regarding intermittent 
catheter usage, Li et al.[20] reviewed five randomised controlled trials 
with a total of 462 subjects with SCI/SCA. There was a significantly 
lower incidence of reported UTIs in the hydrophilic-treated 
(disposable) group when compared with the non-hydrophilic-treated 
(uncoated disposable and multiple use) group. Haematuria was also 
significantly less common in the hydrophilic catheter group than 
in the non-hydrophilic catheter group. Their meta-analysis found 
that UTIs and haematuria are less frequently associated with the use 
of hydrophilic-coated catheters for intermittent catheterisation in 
patients with SCI.
Chartier-Kastler et al.[21] report that compact catheters, designed 
as they are for further discretion, offer a 28% increase in quality 
of life over non-compact intermittent catheters. Given evidence 
of fewer UTIs, less haematuria and better quality of life, compact 
hydrophilic-coated intermittent catherisation appears to be the best 
treatment option. Clinicians will need to base their decision about 
catheterisation technique on clinical judgement, in conjunction with 
the user’s preference.
There are no clear guidelines about the appropriate length of 
time for catheter use if the patient is re-using an uncoated catheter. 
Although a widespread practice, there is no consensus on how many 
times a single-use catheter should be re-used, and the practice is 
regarded as off-label use. Guidelines do, however, refer to clean 
techniques that imply cleaning and storage of these catheters for an 
indeterminate number of times, although again there is no scientific 
evidence for an acceptable number of re-uses. There are also 
insufficient data for recommending a cleaning method for multiple-
use catheters.[22]
Several studies have investigated the advantages and disadvantages 
of re-usable catheters in the home setting, where catheterisation is 
performed by the patient or a caregiver. Available data on intermittent 
catheterisation do not provide convincing evidence that either single 
or multiple uses are superior in all clinical settings. 
Currently, clinicians need to base their decisions about which 
technique and type of catheter to use on clinical judgment, in 
conjunction with specific patient requirements or choice. Differential 
costs of catheters and techniques may also influence decision-
making.[13] It has not been conclusively proven which type of 
catheter (hydrophilic/coated v. non-coated) used for intermittent 
catheterisation is better able to reduce the risk of symptomatic UTI.[23] 
A 2014 Cochrane Review by Prieto et al.[24] compared types of 
catheter design, aseptic catheterisation techniques v. clean technique, 
single-use (sterile) catheters v. multiple-use (clean) catheters, self-
catheterisation v. catheterisation by others and other strategies 
designed to reduce UTI incidence and other complications in 
adults and children using intermittent catheterisation for incomplete 
bladder emptying. Despite a total of 31 trials, it was concluded that 
there was still no convincing evidence that the incidence of UTI is 
affected by any of these strategies.
The conclusion made by the 2014 Cochrane Review strongly 
influenced healthcare providers and agencies to recommend the 
re-use of catheters. However, concerns raised by many clinicians 
regarding these conclusions led to an independent appraisal by 
Christison et al.[25] of the data and analyses presented, which 
identified crucial discrepancies in data extraction and analyses within 
this review. In contrast to Prieto et al.’s[24] conclusion,their analyses 
revealed a trend favouring single over multiple use of catheters. After 
raising these concerns with Cochrane’s acting editor-in-chief, the 
most recent version of the 2014 Cochrane review has been withdrawn 
from publication.
Results from a recent meta-analysis by Rognoni et al.[26] confirmed 
the finding that hydrophilic-coated catheters are associated with a 
reduced risk of UTI among patients using intermittent catheterisation. 
On the other hand, a risk reduction for haematuria associated 
with hydrophilic-coated catheters in general was not demonstrated. 
However, the conclusions of the study are compromised by several 
limitations, such as the heterogeneity of outcomes and definitions, 
the lack of available high-quality randomised controlled trials and a 
higher dropout rate related to hydrophilic catheters. In view of these 
limitations, uncoated catheters may still maintain a place in clinical 
practice. There are limitations and gaps in the evidence base and the 
designation of non-coated catheters as single-use devices.
More importantly, single-use hydrophilic-coated catheters increase 
social participation by saving time, increasing independence and 
reducing the burden related to CIC.[17, 27]
It is recommended that a precautionary principle should be 
adopted, and that patients should be offered a choice between 
hydrophilic and gel reservoir catheters.[23]
Vulnerable patient groups
Vulnerable patient groups using CIC that should be considered for 
hydrophilic-coated intermittent catheters include the following: 
•	 	patients in hospitals, nursing homes or rehabilitation centres
• immunosuppressed patients 
• patients with recurrent UTIs or haematuria.
Economic considerations
By reducing the number of UTIs through the introduction of CIC, it 
has been possible to halve the incidence of renal failure and mortality 
in people with SCAs. The additional costs of CIC are possibly offset 
by the lower rate of UTIs, and the fact that care for a permanent 
catheter is no longer necessary.[28]
The choice of catheter type for intermittent catheterisation is 
currently influenced by economic considerations, in the selection 
of the re-use of non-coated, single-use non-coated, or hydrophilic-
coated catheters. No economic analysis has yet been conducted in 
SA comparing any of these techniques, although re-use of single-use 
catheters is currently most prevalent.
Bermingham et al.[23] performed a cost-effectiveness analysis 
using data from trials with various intermittent catheter types, 
finding a slight difference among them in the risks of symptomatic 
UTIs. The analysis, however, focused only on the acute treatment of 
symptomatic UTIs, and did not consider their lifetime downstream 
sequelae, such as renal function. However, this analysis did not 
include the largest study in hospitalised SCI patients, which had 
previously compared UTI incidence rates for single-use hydrophilic-
coated and uncoated catheters.[19]
Clark et al.[29] used a probabilistic decision analysis to investigate 
the cost-effectiveness of hydrophilic catheters v. uncoated catheters 
using a lifetime perspective. Hydrophilic catheters were estimated 
to be a more cost-effective solution when compared with uncoated 
catheters with a relatively low incremental cost-effectiveness ratio in 
the UK context.
Consideration of the patient’s quality of life and needs, their 
therapeutic goals and economic status must become the measure 
of care. To this end, a system of ongoing exchange and regular 
discussion should be established with all those involved in the care 
process, e.g. patients, health insurance funds, specialist physicians 
and providers and manufacturers of medical technical aids. 
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There have been no studies taking into account economic 
considerations for the SA healthcare environment regarding SCA 
care, and therefore inadequate data exist to make recommendations 
on the cost-effectiveness of bladder management strategies in SA.
Conclusion
Management of the urinary tract in people with SCA is continuing 
to evolve. Unfortunately, the scientific evidence base on which 
treatment decisions must be made is inconclusive. It is therefore 
important that clinicians take heed of the lessons that have been 
learnt in SCI centres over the decades, but, at the same time, continue 
to question the accepted wisdom and subject it to scientific challenge.
The care of this group of patients is hugely rewarding for the 
treating clinical team, as high-quality urinary tract management 
has a major positive impact on a patient’s quality of life, their health 
outcome and the cost-effectiveness of treatment. On an international 
scale, there is an urgent need to devise cost-effective SCI management 
regimes that translate the results of the best SCI centres into the 
healthcare systems of the developing world.[23]
It is the recommendation of CAP that bladder management 
decision-making in the spinal cord-afflicted population in SA needs 
specialised care. A phased approach will improve the attention 
to detail in our resource-challenged environment. This includes 
appropriate early care (phase 1), expert assessment of the neurogenic 
bladder and initiation of appropriate choice of long-term strategy 
(phase 2) and mandatory follow-up regimes for long-term care 
(phase 3). This approach will equate to improved long-term positive 
outcomes.
Medical practitioners should promote confirmed safe, non-
infecting and non-traumatic techniques for bladder management. 
In SA, the Health Professions Act No. 56 of 1974[30] requires 
practitioners to provide patients with information on the treatment 
options available, and to obtain their informed consent for the 
treatment subsequently chosen. Part of this process is a discussion 
about the benefits, risks and costs of the options available.
Effective communication between healthcare professionals and 
patients is essential, where treatment and care should consider 
patient needs, preferences and circumstances.[31] The National Health 
Act No. 61 of 2003[32] also requires that practitioners should offer 
‘the best possible care at a cost-effective rate’.[33] Cost-effectiveness 
and low cost are not equivalent terms. The issue is rendered more 
difficult by the fact that we lack measurements of the total treatment 
and care pathway savings in the medium to longer term that would 
result from deciding against inferior care. Reduced complications and 
comorbidities, and earlier return to normal activities, are examples of 
such unmeasured outcomes.
*The Continence Advisory Panel (CAP) is an interest group of the 
Southern African Spinal Cord Association (SASCA). 
These recommendations were reviewed externally by the SA Urological 
Association and international experts in the management of the spinal 
cord-afflicted and the neurogenic bladder.
These recommendations will be reviewed every 3 years, or earlier should 
further evidence demand such a review.
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